Novel drugs in clinical development for hepatocellular carcinoma
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/13543784.2015.1058776
Reference47 articles.
1. Sorafenib in Advanced Hepatocellular Carcinoma
2. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
3. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
4. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Artemordins A—S, Cadinane‐Type Sesquiterpenoid Dimers from Artemisia ordosica and Their Antihepatoma Activities;Chinese Journal of Chemistry;2024-03-07
2. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis;Expert Opinion on Drug Safety;2022-11-29
3. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?;Frontiers in Oncology;2021-12-17
4. Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.;Translational Oncology;2021-12
5. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges;Expert Review of Gastroenterology & Hepatology;2021-08-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3